NCT01796964View on ClinicalTrials.gov

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

PHASE2CompletedINTERVENTIONAL

Enrollment

173

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

August 31, 2014

Conditions

Exudative Age-Related Macular Degeneration

Interventions

DRUG

ESBA1008 solution

For intravitreal (IVT) injection

DRUG

Aflibercept

For intravitreal (IVT) injection

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alcon Research

INDUSTRY